相关实验视频

Updated: May 26, 2025

Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound

Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound

Published on: April 21, 2023

在手术前优化慢性阻塞性肺部疾病患者可能会减少并发症,并改善内内血管再血管化的结果

Renxi Li^1,2, Rachel Silverman¹, Anton Sidawy²

¹School of Medicine and Health Sciences, The George Washington University, Washington, DC, USA.

Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists

|February 21, 2025

概括

患有慢性阻塞性肺病 (COPD) 的患者在下内血管再血管化后面临死亡和并发症的风险增加. 在COPD患者的手术前查和优化对于改善结果至关重要.

科学领域:

血管外科血管外科
肺部病理学肺部病理学
心脏病学心脏病学

背景情况:

周围动脉疾病 (PAD) 和慢性阻塞性肺病 (COPD) 分享炎症途径.
了解COPD对内内血管再血管化结果的影响至关重要.

研究的目的:

为了分析30天COPD患者的术后结果,这些患者正在接受下血管内血管再循环.
评估COPD对术后并发症的独立影响.

主要方法:

使用了ACS-NSQIP数据库 (2012-2022) 针对内内血管再血管化病例.
雇佣1: 1倾向性得分匹配,以比较COPD和非COPD队列.
不包括18岁以下的患者和紧急病例.

主要成果:

慢性肺炎患者 (10.21%) 的30天死亡率 (3.24% vs 2.18%),主要心血管不良事件 (3.48% vs 2.47%),肺部并发症 (3.24% vs 2.02%) 和再入院 (15.41% vs 13.23%) 的风险显著增加.
倾向性得分匹配确保了各组之间可比的基线特征.

结论:

慢性肺炎是30天死亡率和心肺复发症增加的独立危险因素,后的内内血管再血管化.
在程序前识别和优化COPD患者,可能通过迷你呼吸计和定制治疗,可以减轻风险.

关键词:

慢性阻塞性肺病慢性阻塞性肺病这是内血管内血管的内血管.死亡率死亡率周围血管疾病是周围血管疾病.重新血管化的过程.

更多相关视频

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Published on: September 22, 2020

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...